Shareholders are pleased with Bionano Genomics' 20% stake rise despite a 10% growth in losses. Analysts predict a revenue increase and reduced losses, but the consensus price target remains low, indicating pessimism about the company's future.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing